• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

长效帕西瑞肽与多巴胺激动剂联合治疗成功切除多激素垂体大腺瘤

Successful debulking of plurihormonal pituitary macroadenoma with long-acting pasireotide and dopamine agonist combination therapy.

作者信息

Jerkins Terri W, Jerkins Randy K, Franklin Robbi

机构信息

Midstate Endocrinology Associates Nashville Tennessee.

College of Pharmacy Lipscomb University Nashville Tennessee.

出版信息

Clin Case Rep. 2019 Jan 28;7(3):445-451. doi: 10.1002/ccr3.1961. eCollection 2019 Mar.

DOI:10.1002/ccr3.1961
PMID:30899469
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6406151/
Abstract

Long-acting pasireotide and bromocriptine provided biochemical control of growth hormone and prolactin in a patient with plurihormonal pituitary macroadenoma, allowing near-complete tumor excision while restoring pituitary function and avoiding adjunctive radiotherapy. Pasireotide initiation resulted in hyperglycemia, which stabilized after a few months and resolved upon pasireotide discontinuation (ACCESS; NCT01995734).

摘要

长效帕瑞肽和溴隐亭使一名患有多激素垂体大腺瘤的患者的生长激素和催乳素得到生化控制，从而在恢复垂体功能并避免辅助放疗的同时实现了肿瘤的近乎完全切除。开始使用帕瑞肽导致血糖升高，几个月后血糖稳定，停用帕瑞肽后血糖恢复正常（ACCESS；NCT01995734）。

相似文献

1
Successful debulking of plurihormonal pituitary macroadenoma with long-acting pasireotide and dopamine agonist combination therapy.长效帕西瑞肽与多巴胺激动剂联合治疗成功切除多激素垂体大腺瘤
Clin Case Rep. 2019 Jan 28;7(3):445-451. doi: 10.1002/ccr3.1961. eCollection 2019 Mar.
2
Pasireotide therapy in a rare and unusual case of plurihormonal pituitary macroadenoma.帕西瑞肽治疗一例罕见的多激素垂体大腺瘤
Endocrinol Diabetes Metab Case Rep. 2013;2013:130026. doi: 10.1530/EDM-13-0026. Epub 2013 Aug 30.
3
Analgesic effect of long-acting somatostatin receptor agonist pasireotide in a patient with acromegaly and intractable headaches.长效生长抑素受体激动剂帕西瑞肽对一名肢端肥大症伴顽固性头痛患者的镇痛作用。
BMJ Case Rep. 2018 Jun 19;2018:bcr-2017-219686. doi: 10.1136/bcr-2017-219686.
4
Pasireotide in an insulin-requiring diabetic acromegalic patient without worsening of hyperglycemia.帕西瑞肽用于一名需要胰岛素治疗的糖尿病肢端肥大症患者，未导致高血糖恶化。
Endocrinol Diabetes Metab Case Rep. 2017 May 13;2017. doi: 10.1530/EDM-17-0003. eCollection 2017.
5
Plurihormonal pituitary macroadenoma:  a case report.多激素垂体大腺瘤：一例报告。
J Med Case Rep. 2021 Jul 29;15(1):407. doi: 10.1186/s13256-021-02948-6.
6
Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly.使用帕瑞肽长效释放制剂成功治疗库欣病合并生化性肢端肥大症。
Intern Med. 2021 Apr 1;60(7):1047-1053. doi: 10.2169/internalmedicine.4663-20. Epub 2020 Nov 9.
7
Pituitary acting drugs: cabergoline and pasireotide.垂体作用药物：卡麦角林和培高利特。
Pituitary. 2022 Oct;25(5):722-725. doi: 10.1007/s11102-022-01238-8. Epub 2022 Jun 7.
8
Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.术前帕瑞肽治疗对侵袭性奥曲肽抵抗性肢端肥大症的影响。
Endocr J. 2018 Oct 29;65(10):1061-1067. doi: 10.1507/endocrj.EJ17-0487. Epub 2018 Aug 4.
9
Pasireotide: A potential therapeutic alternative for resistant prolactinoma.培高利特：一种抵抗性泌乳素瘤的潜在治疗选择。
Ann Endocrinol (Paris). 2019 Apr;80(2):84-88. doi: 10.1016/j.ando.2018.07.013. Epub 2018 Sep 25.
10
Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma.一名无排卵女性，因分泌促卵泡激素的多激素垂体微腺瘤并发卵巢过度刺激综合征，经溴隐亭治疗后成功妊娠。
J Clin Endocrinol Metab. 2003 May;88(5):1988-93. doi: 10.1210/jc.2002-021820.

本文引用的文献

1
Late presentation of acromegaly in medically controlled prolactinoma patients.在接受药物治疗的泌乳素瘤患者中肢端肥大症的迟发表现。
Endocrinol Diabetes Metab Case Rep. 2016;2016. doi: 10.1530/EDM-16-0069. Epub 2016 Oct 17.
2
Acromegaly: clinical features at diagnosis.肢端肥大症：诊断时的临床特征
Pituitary. 2017 Feb;20(1):22-32. doi: 10.1007/s11102-016-0772-8.
3
Acromegaly: an endocrine society clinical practice guideline.肢端肥大症：内分泌学会临床实践指南。
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51. doi: 10.1210/jc.2014-2700. Epub 2014 Oct 30.
4
Synchronous GH- and prolactin-secreting pituitary adenomas.同步分泌生长激素和催乳素的垂体腺瘤。
Endocrinol Diabetes Metab Case Rep. 2014;2014:140052. doi: 10.1530/EDM-14-0052. Epub 2014 Sep 1.
5
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.培高利特对比奥曲肽或兰瑞肽治疗未能充分控制的肢端肥大症患者（PAOLA）：一项随机、3 期试验。
Lancet Diabetes Endocrinol. 2014 Nov;2(11):875-84. doi: 10.1016/S2213-8587(14)70169-X. Epub 2014 Sep 24.
6
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.帕西瑞肽长效注射剂在肢端肥大症患者中维持对生长激素（GH）和胰岛素样生长因子-1（IGF-1）的抑制作用长达25个月：一项随机、双盲、多中心III期研究的盲法延长期结果
Pituitary. 2015 Jun;18(3):385-94. doi: 10.1007/s11102-014-0585-6.
7
Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis.肢端肥大症合并大腺瘤患者的术前生长抑素类似物治疗。一项荟萃分析。
Brain Dev. 2015 Feb;37(2):181-90. doi: 10.1016/j.braindev.2014.04.009. Epub 2014 May 10.
8
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.培高利特与奥曲肽治疗肢端肥大症的头对头优效性研究。
J Clin Endocrinol Metab. 2014 Mar;99(3):791-9. doi: 10.1210/jc.2013-2480. Epub 2014 Jan 13.
9
Results of endoscopic transsphenoidal pituitary surgery in 40 patients with a growth hormone-secreting macroadenoma.40 例生长激素分泌型垂体大腺瘤经鼻蝶窦内镜垂体瘤切除术的结果。
Acta Neurochir (Wien). 2011 Jul;153(7):1391-9. doi: 10.1007/s00701-011-0959-8. Epub 2011 Feb 24.
10
Growth hormone-secreting adenomas: pathology and cell biology.生长激素分泌腺瘤：病理学与细胞生物学。
Neurosurg Focus. 2010 Oct;29(4):E2. doi: 10.3171/2010.7.FOCUS10169.